AIMS/HYPOTHESIS: Acute hyperglycaemia rapidly suppresses endogenous glucose production (EGP) in non-diabetic individuals, mainly by inhibiting glycogenolysis. Loss of this 'glucose effectiveness' contributes to fasting hyperglycaemia in type 2 diabetes. Elevated NEFA levels characteristic of type 2 diabetes impair glucose effectiveness, although the mechanism is not fully understood. Therefore we examined the impact of increasing NEFA levels on the ability of hyperglycaemia to regulate pathways of EGP. METHODS: We performed 4 h 'pancreatic clamp' studies (somatostatin; basal glucagon/growth hormone/insulin) in seven non-diabetic individuals. Glucose fluxes (D-[6,6-(2)H(2)]glucose) and hepatic glycogen concentrations ((13)C magnetic resonance spectroscopy) were quantified under three conditions: euglycaemia, hyperglycaemia and hyperglycaemia with elevated NEFA (HY-NEFA). RESULTS: EGP was suppressed by hyperglycaemia, but not by HY-NEFA. Hepatic glycogen concentration decreased ~14% with prolonged fasting during euglycaemia and increased by ~12% with hyperglycaemia. In contrast, raising NEFA levels in HY-NEFA caused a substantial ~23% reduction in hepatic glycogen concentration. Moreover, rates of gluconeogenesis were decreased with hyperglycaemia, but increased with HY-NEFA. CONCLUSIONS/ INTERPRETATION: Increased NEFA appear to profoundly blunt the ability of hyperglycaemia to inhibit net glycogenolysis under basal hormonal conditions.
AIMS/HYPOTHESIS: Acute hyperglycaemia rapidly suppresses endogenous glucose production (EGP) in non-diabetic individuals, mainly by inhibiting glycogenolysis. Loss of this 'glucose effectiveness' contributes to fasting hyperglycaemia in type 2 diabetes. Elevated NEFA levels characteristic of type 2 diabetes impair glucose effectiveness, although the mechanism is not fully understood. Therefore we examined the impact of increasing NEFA levels on the ability of hyperglycaemia to regulate pathways of EGP. METHODS: We performed 4 h 'pancreatic clamp' studies (somatostatin; basal glucagon/growth hormone/insulin) in seven non-diabetic individuals. Glucose fluxes (D-[6,6-(2)H(2)]glucose) and hepatic glycogen concentrations ((13)C magnetic resonance spectroscopy) were quantified under three conditions: euglycaemia, hyperglycaemia and hyperglycaemia with elevated NEFA (HY-NEFA). RESULTS:EGP was suppressed by hyperglycaemia, but not by HY-NEFA. Hepatic glycogen concentration decreased ~14% with prolonged fasting during euglycaemia and increased by ~12% with hyperglycaemia. In contrast, raising NEFA levels in HY-NEFA caused a substantial ~23% reduction in hepatic glycogen concentration. Moreover, rates of gluconeogenesis were decreased with hyperglycaemia, but increased with HY-NEFA. CONCLUSIONS/ INTERPRETATION: Increased NEFA appear to profoundly blunt the ability of hyperglycaemia to inhibit net glycogenolysis under basal hormonal conditions.
Authors: Roman Hovorka; Harsha Jayatillake; Eduard Rogatsky; Vlad Tomuta; Tomas Hovorka; Daniel T Stein Journal: Am J Physiol Endocrinol Metab Date: 2007-05-22 Impact factor: 4.310
Authors: M Roden; H Stingl; V Chandramouli; W C Schumann; A Hofer; B R Landau; P Nowotny; W Waldhäusl; G I Shulman Journal: Diabetes Date: 2000-05 Impact factor: 9.461
Authors: J H Hwang; G Perseghin; D L Rothman; G W Cline; I Magnusson; K F Petersen; G I Shulman Journal: J Clin Invest Date: 1995-02 Impact factor: 14.808
Authors: Luke W Johnston; Stewart B Harris; Ravi Retnakaran; Adria Giacca; Zhen Liu; Richard P Bazinet; Anthony J Hanley Journal: Diabetologia Date: 2017-12-24 Impact factor: 10.122
Authors: Hannah Pallubinsky; Esther Phielix; Bas Dautzenberg; Gert Schaart; Niels J Connell; Vera de Wit-Verheggen; Bas Havekes; Marleen A van Baak; Patrick Schrauwen; Wouter D van Marken Lichtenbelt Journal: Acta Physiol (Oxf) Date: 2020-06-01 Impact factor: 6.311